世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

北米のがんバイオマーカー市場予測 2019-2027年

NORTH AMERICA CANCER BIOMARKER MARKET FORECAST 2019-2027

 

出版社 出版年月電子版価格 ページ数
Inkwood Research
インクウッドリサーチ
2019年1月US$1,250
シングルユーザライセンス(印刷不可PDF)
80

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

サマリー

この調査レポートは北米のがんバイオマーカー市場を分析・予測したInkwood Researchの市場調査報告書です。

Overview

KEY FINDINGS
The North American cancer biomarker market is all set to expand with a CAGR of 10.41% between the forecasted years of 2019-2027. The region holds the highest share in the global cancer biomarker market and also contribute the maximum revenue in the year 2018. The development in the precision and speed of diagnosis and rising production of highly specific drugs are majorly responsible for the surge in the North American cancer biomarker market.

MARKET INSIGHTS

The government institutions and private organizations have initiated to invest huge funds in enhancing research activities for cancer. This is one of the major factor augmenting the market growth in the region. Moreover, the developed economies like the United States and Canada are also majorly contributing to the market. However, rigorous regulatory agenda and a dearth of skilled workers are the growing concerns to the market.

COMPETITIVE INSIGHTS

Some of the leading companies in the market are Illumina, Inc., Diadexus Inc. (Acquired By Diazyme Laboratories), Abbott Laboratories, Agilent Technologies, Inc., Becton Dickinson and Company, Roche Diagnostics Ltd, Sanofi, Agendia N.V., Aureon Biosciences, Inc., Astellas Pharma Inc., Celgene Corporation, Clarient, Inc. (Acquired By Neogenomics Laboratories), Bristol-Myers Squibb, Beckman Coulter and Qiagen N.V.



目次

Table of Contents

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. OMIC TECHNOLOGY GENERATED THE HIGHEST REVENUE IN TERMS OF PROFILING TECHNOLOGY
3.2.2. GLYCO BIOMARKERS ARE THE FASTEST GROWING CANCER BIOMARKERS
3.2.3. BREAST CANCER HOLDS THE LARGEST MARKET SHARE IN TERMS OF CANCER TYPE
3.2.4. DIAGNOSTICS APPLICATION IS THE MAJORLY USED CANCER BIOMARKER APPLICATION
4. MARKET DYNAMICS
4.1. MARKET SCOPE & DEFINITION
4.2. MARKET DRIVERS
4.2.1. GROWING PREVALENCE ON RESEARCH OF CANCER BIOMARKERS
4.2.2. ENCOURAGEMENT FOR BIOMARKER DEVELOPMENT BY FDA
4.2.3. IMPROVED PRECISION AND SPEED OF DIAGNOSIS
4.2.4. HIGH INVESTMENT THROUGH GOVERNMENT AND PRIVATE FUNDS IN CANCER RELATED RESEARCH
4.2.5. DEVELOPMENT OF HIGHLY SPECIFIC DRUGS
4.2.6. GROWTH IN IMPORTANCE OF BIOLOGICAL AND TARGETED DRUG THERAPIES
4.2.7. TECHNOLOGICAL ADVANCEMENTS
4.2.8. GROWING PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS
4.3. MARKET RESTRAINTS
4.3.1. POOR COMPENSATION STRUCTURES
4.3.2. LOW ESTIMATED RATE OF SUCCESSFUL CLINICAL TRIALS OF BIOMARKERS
4.3.3. TECHNICAL ISSUES RELATED TO CANCER BIOMARKERS
4.3.4. HIGH COST OF DRUG DEVELOPMENT
4.3.5. UNCLEAR GOVERNMENT REGULATION AND REIMBURSEMENT POLICIES
4.4. MARKET OPPORTUNITIES
4.4.1. WIDE OPPORTUNITY TO GROW IN PERSONALIZED MEDICATION
4.4.2. SUPPORTS ON BIOMARKERS TEST
4.4.3. GROWING NUMBER OF CANCER PATIENTS AND GROWING MEDICAL TOURISM IN EMERGING ECONOMIES
4.4.4. ADVANCEMENT OF CANCER DRUGS RESEARCH
4.5. MARKET CHALLENGES
4.5.1. LACKING ACCEPTANCE OF THE CANCER BIOMARKER
4.5.2. UNFAVORABLE COMPENSATION SITUATION
4.5.3. HIGH COST OF DEVELOPING COMPANION DIAGNOSTICS
4.5.4. RIGOROUS REGULATORY AGENDA
4.5.5. DEARTH OF SKILFUL WORKERS
5. MARKET BY PROFILING TECHNOLOGY
5.1. OMIC TECHNOLOGY
5.2. IMAGING TECHNOLOGIES
5.3. IMMUNOASSAYS
5.4. CYTOGENETIC-BASED TESTS
6. MARKET BY BIOMARKER
6.1. GENETIC BIOMARKERS
6.2. PROTEIN BIOMARKERS
6.3. GLYCO BIOMARKERS
7. MARKET BY CANCER TYPE
7.1. LUNG CANCER
7.2. BREAST CANCER
7.3. COLORECTAL CANCER
7.4. PROSTATE CANCER
7.5. STOMACH CANCER
7.6. OTHERS CANCER TYPE
8. MARKET BY APPLICATION
8.1. DIAGNOSTICS
8.2. DRUG DISCOVERY AND DEVELOPMENT
8.3. PROGNOSTICS
8.4. RISK ASSESSMENT
8.5. OTHER APPLICATION
9. KEY ANALYTICS
9.1. PORTER’S FIVE FORCE ANALYSIS
9.1.1. THREAT OF NEW ENTRANTS
9.1.2. THREAT OF SUBSTITUTE PRODUCT
9.1.3. BARGAINING POWER OF BUYER
9.1.4. BARGAINING POWER OF SUPPLIERS
9.1.5. INTENSITY OF COMPETITIVE RIVALRY
9.2. KEY BUYING CRITERIA
9.2.1. PRICING
9.2.2. EFFICACY
9.2.3. APPLICATION AND EFFECTIVENESS
9.3. PATENT ANALYSIS
9.4. ONCOLOGY DRUGS APPROVALS BY THE FDA
9.5. OPPORTUNITY MATRIX
10. GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1. THE UNITED STATES
10.1.2. CANADA
11. COMPETITIVE LANDSCAPE
11.1. MARKET SHARE ANALYSIS
11.2. COMPANY PROFILES
11.2.1. ABBOTT LABORATORIES
11.2.1.1. COMPANY OVERVIEW
11.2.1.2. PRODUCT PORTFOLIO
11.2.1.3. SCOT ANALYSIS
11.2.1.4. STRATEGIC INITIATIVES
11.2.2. AGENDIA N.V.
11.2.2.1. COMPANY OVERVIEW
11.2.2.2. PRODUCT PORTFOLIO
11.2.2.3. SCOT ANALYSIS
11.2.2.4. STRATEGIC INITIATIVES
11.2.3. AGILENT TECHNOLOGIES, INC.
11.2.3.1. COMPANY OVERVIEW
11.2.3.2. PRODUCT PORTFOLIO
11.2.3.3. SCOT ANALYSIS
11.2.3.4. STRATEGIC INITIATIVES
11.2.4. AUREON BIOSCIENCES, INC
11.2.4.1. COMPANY OVERVIEW
11.2.4.2. PRODUCT PORTFOLIO
11.2.4.3. SCOT ANALYSIS
11.2.4.4. STRATEGIC INITIATIVES
11.2.5. ASTELLAS PHARMA INC.
11.2.5.1. COMPANY OVERVIEW
11.2.5.2. PRODUCT PORTFOLIO
11.2.5.3. SCOT ANALYSIS
11.2.5.4. STRATEGIC INITIATIVES
11.2.6. BECKMAN COULTER
11.2.6.1. COMPANY OVERVIEW
11.2.6.2. PRODUCT PORTFOLIO
11.2.6.3. SCOT ANALYSIS
11.2.6.4. STRATEGIC INITIATIVES
11.2.7. BECTON DICKINSON AND COMPANY
11.2.7.1. COMPANY OVERVIEW
11.2.7.2. PRODUCT PORTFOLIO
11.2.7.3. SCOT ANALYSIS
11.2.7.4. STRATEGIC INITIATIVES
11.2.8. BRISTOL-MYERS SQUIBB
11.2.8.1. COMPANY PROFILES
11.2.8.2. PRODUCT PORTFOLIO
11.2.8.3. SCOT ANALYSIS
11.2.8.4. STRATEGIC INITIATIVES
11.2.9. CELGENE CORPORATION
11.2.9.1. COMPANY OVERVIEW
11.2.9.2. PRODUCT PORTFOLIO
11.2.9.3. SCOT ANALYSIS
11.2.9.4. STRATEGIC INITIATIVES
11.2.10. CLARIENT, INC. (ACQUIRED BY NEOGENOMICS LABORATORIES)
11.2.10.1. COMPANY OVERVIEW
11.2.10.2. PRODUCT PORTFOLIO
11.2.10.3. SCOT ANALYSIS
11.2.10.4. STRATEGIC INITIATIVES
11.2.11. DIADEXUS INC. (ACQUIRED BY DIAZYME LABORATORIES)
11.2.11.1. COMPANY OVERVIEW
11.2.11.2. PRODUCT PORTFOLIO
11.2.11.3. SCOT ANALYSIS
11.2.11.4. STRATEGIC INITIATIVES
11.2.12. ILLUMINA, INC.
11.2.12.1. COMPANY OVERVIEW
11.2.12.2. PRODUCT PORTFOLIO
11.2.12.3. SCOT ANALYSIS
11.2.12.4. STRATEGIC INITIATIVES
11.2.13. ROCHE DIAGNOSTICS LTD
11.2.13.1. COMPANY OVERVIEW
11.2.13.2. PRODUCT PORTFOLIO
11.2.13.3. SCOT ANALYSIS
11.2.13.4. STRATEGIC INITIATIVES
11.2.14. SANOFI
11.2.14.1. COMPANY OVERVIEW
11.2.14.2. PRODUCTS PORTFOLIO
11.2.14.3. SCOT ANALYSIS
11.2.14.4. STRATEGIC INITIATIVES
11.2.15. QIAGEN N.V.
11.2.15.1. COMPANY OVERVIEW
11.2.15.2. PRODUCT PORTFOLIO
11.2.15.3. SCOT ANALYSIS
11.2.15.4. STRATEGIC INITIATIVES





TABLE LIST
TABLE 1 NORTH AMERICA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
TABLE 2 RECENT RESEARCH ON BIOMARKERS
TABLE 3 LIST OF FDA APPROVED PROTEIN CANCER BIOMARKERS
TABLE 4 POTENTIAL CLINICAL USE OF CANCER BIOMARKERS
TABLE 5 MEDICAL TOURISM PRICES IN US DOLLAR
TABLE 6 NORTH AMERICA CANCER BIOMARKER MARKET BY PROFILING TECHNOLOGY 2019-2027 ($ MILLION)
TABLE 7 NORTH AMERICA OMIC TECHNOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 8 NORTH AMERICA IMAGING TECHNOLOGIES MARKET 2019-2027 ($ MILLION)
TABLE 9 NORTH AMERICA IMMUNOASSAYS MARKET 2019-2027 ($ MILLION)
TABLE 10 NORTH AMERICA CYTOGENETICS-BASED TESTS MARKET 2019-2027 ($ MILLION)
TABLE 11 NORTH AMERICA CANCER BIOMARKER MARKET BY BIOMARKER 2019-2027 ($ MILLION)
TABLE 12 NORTH AMERICA GENETIC BIOMARKERS MARKET 2019-2027 ($ MILLION)
TABLE 13 NORTH AMERICA PROTEIN BIOMARKERS MARKET 2019-2027 ($ MILLION)
TABLE 14 NORTH AMERICA GLYCO BIOMARKERS MARKET 2019-2027 ($ MILLION)
TABLE 15 NORTH AMERICA CANCER BIOMARKER MARKET BY CANCER TYPE 2019-2027 ($ MILLION)
TABLE 16 NORTH AMERICA LUNG CANCER MARKET 2019-2027 ($ MILLION)
TABLE 17 NORTH AMERICA BREAST CANCER MARKET 2019-2027 ($ MILLION)
TABLE 18 NORTH AMERICA COLORECTAL CANCER MARKET 2019-2027 ($ MILLION)
TABLE 19 NORTH AMERICA PROSTATE CANCER MARKET 2019-2027 ($ MILLION)
TABLE 20 NORTH AMERICA STOMACH CANCER MARKET 2019-2027 ($ MILLION)
TABLE 21 NORTH AMERICA OTHERS CANCER TYPE MARKET 2019-2027 ($ MILLION)
TABLE 22 NORTH AMERICA CANCER BIOMARKER MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 23 NORTH AMERICA DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
TABLE 24 NORTH AMERICA DRUG DISCOVERY AND DEVELOPMENT MARKET 2019-2027 ($ MILLION)
TABLE 25 NORTH AMERICA PROGNOSTICS MARKET 2019-2027 ($ MILLION)
TABLE 26 NORTH AMERICA RISK ASSESSMENT MARKET 2019-2027 ($ MILLION)
TABLE 27 NORTH AMERICA OTHER APPLICATION MARKET 2019-2027 ($ MILLION)
TABLE 28 PATENT PRODUCTS WITH THE EXPIRY DATE
TABLE 29 PATENT PUBLICATIONS RELATED TO BREAST CANCER 2017
TABLE 30 PATENT PUBLICATIONS RELATED TO PROSTATE CANCER 2017
TABLE 31 PATENT PUBLICATIONS RELATED TO LUNG CANCER 2017
TABLE 32 NORTH AMERICA CANCER BIOMARKER MARKET BY COUNTRY 2019-2027 ($ MILLION)



FIGURES LIST
FIGURE 1 NORTH AMERICA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 2 PHARMACOGENOMIC BIOMARKERS INFORMATION IN DRUG LABELING
FIGURE 3 PERCENTAGE OF PATIENTS INEFFECTIVE FOR PARTICULAR DRUG (%)
FIGURE 4 LIST OF CLEARED OR APPROVED COMPANION DIAGNOSTIC DEVICES (IMAGING TOOLS AND IN VITRO) BY FDA
FIGURE 5 NORTH AMERICA CANCER BIOMARKER MARKET SHARE BY PROFILING TECHNOLOGY 2018 & 2027 (%)
FIGURE 6 NORTH AMERICA CANCER BIOMARKER MARKET SHARE BY BIOMARKER 2018 & 2027 (%)
FIGURE 7 NORTH AMERICA CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
FIGURE 8 NORTH AMERICA CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
FIGURE 9 PORTER’S FIVE FORCE ANALYSIS
FIGURE 10 NORTH AMERICA CANCER BIOMARKER MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
FIGURE 11 THE UNITED STATES CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 12 PROPORTION OF DEATH CAUSED BY CANCER AND OTHER DISEASE IN CANADA (%)
FIGURE 13 CANADA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 14 MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)

List of Tables

TABLE LIST
TABLE 1 NORTH AMERICA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
TABLE 2 RECENT RESEARCH ON BIOMARKERS
TABLE 3 LIST OF FDA APPROVED PROTEIN CANCER BIOMARKERS
TABLE 4 POTENTIAL CLINICAL USE OF CANCER BIOMARKERS
TABLE 5 MEDICAL TOURISM PRICES IN US DOLLAR
TABLE 6 NORTH AMERICA CANCER BIOMARKER MARKET BY PROFILING TECHNOLOGY 2019-2027 ($ MILLION)
TABLE 7 NORTH AMERICA OMIC TECHNOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 8 NORTH AMERICA IMAGING TECHNOLOGIES MARKET 2019-2027 ($ MILLION)
TABLE 9 NORTH AMERICA IMMUNOASSAYS MARKET 2019-2027 ($ MILLION)
TABLE 10 NORTH AMERICA CYTOGENETICS-BASED TESTS MARKET 2019-2027 ($ MILLION)
TABLE 11 NORTH AMERICA CANCER BIOMARKER MARKET BY BIOMARKER 2019-2027 ($ MILLION)
TABLE 12 NORTH AMERICA GENETIC BIOMARKERS MARKET 2019-2027 ($ MILLION)
TABLE 13 NORTH AMERICA PROTEIN BIOMARKERS MARKET 2019-2027 ($ MILLION)
TABLE 14 NORTH AMERICA GLYCO BIOMARKERS MARKET 2019-2027 ($ MILLION)
TABLE 15 NORTH AMERICA CANCER BIOMARKER MARKET BY CANCER TYPE 2019-2027 ($ MILLION)
TABLE 16 NORTH AMERICA LUNG CANCER MARKET 2019-2027 ($ MILLION)
TABLE 17 NORTH AMERICA BREAST CANCER MARKET 2019-2027 ($ MILLION)
TABLE 18 NORTH AMERICA COLORECTAL CANCER MARKET 2019-2027 ($ MILLION)
TABLE 19 NORTH AMERICA PROSTATE CANCER MARKET 2019-2027 ($ MILLION)
TABLE 20 NORTH AMERICA STOMACH CANCER MARKET 2019-2027 ($ MILLION)
TABLE 21 NORTH AMERICA OTHERS CANCER TYPE MARKET 2019-2027 ($ MILLION)
TABLE 22 NORTH AMERICA CANCER BIOMARKER MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 23 NORTH AMERICA DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
TABLE 24 NORTH AMERICA DRUG DISCOVERY AND DEVELOPMENT MARKET 2019-2027 ($ MILLION)
TABLE 25 NORTH AMERICA PROGNOSTICS MARKET 2019-2027 ($ MILLION)
TABLE 26 NORTH AMERICA RISK ASSESSMENT MARKET 2019-2027 ($ MILLION)
TABLE 27 NORTH AMERICA OTHER APPLICATION MARKET 2019-2027 ($ MILLION)
TABLE 28 PATENT PRODUCTS WITH THE EXPIRY DATE
TABLE 29 PATENT PUBLICATIONS RELATED TO BREAST CANCER 2017
TABLE 30 PATENT PUBLICATIONS RELATED TO PROSTATE CANCER 2017
TABLE 31 PATENT PUBLICATIONS RELATED TO LUNG CANCER 2017
TABLE 32 NORTH AMERICA CANCER BIOMARKER MARKET BY COUNTRY 2019-2027 ($ MILLION)

List of Figures

FIGURES LIST
FIGURE 1 NORTH AMERICA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 2 PHARMACOGENOMIC BIOMARKERS INFORMATION IN DRUG LABELING
FIGURE 3 PERCENTAGE OF PATIENTS INEFFECTIVE FOR PARTICULAR DRUG (%)
FIGURE 4 LIST OF CLEARED OR APPROVED COMPANION DIAGNOSTIC DEVICES (IMAGING TOOLS AND IN VITRO) BY FDA
FIGURE 5 NORTH AMERICA CANCER BIOMARKER MARKET SHARE BY PROFILING TECHNOLOGY 2018 & 2027 (%)
FIGURE 6 NORTH AMERICA CANCER BIOMARKER MARKET SHARE BY BIOMARKER 2018 & 2027 (%)
FIGURE 7 NORTH AMERICA CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
FIGURE 8 NORTH AMERICA CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
FIGURE 9 PORTER’S FIVE FORCE ANALYSIS
FIGURE 10 NORTH AMERICA CANCER BIOMARKER MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
FIGURE 11 THE UNITED STATES CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 12 PROPORTION OF DEATH CAUSED BY CANCER AND OTHER DISEASE IN CANADA (%)
FIGURE 13 CANADA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 14 MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る